EMA/230119/2012

European Medicines Agency decision

P/0102/2012

of 30 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0102/2012

of 30 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Les Laboratoires Servier on 6 June 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 April 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for agomelatine (Valdoxan, Thymanax), film-coated tablet, oral use, details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for agomelatine (Valdoxan, Thymanax), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for agomelatine (Valdoxan, Thymanax), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Les Laboratoires Servier, 50, rue Carnot, 92284 - Suresnes cedex, France.

Done at London, 30 May 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/68955/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001181-PIP01-11

Scope of the application

Active substance(s):

Agomelatine

Invented name:

Valdoxan

Thymanax

Condition(s):

Treatment of major depressive episodes

Treatment of generalised anxiety disorder

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Les Laboratoires Servier

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Les Laboratoires Servier submitted for agreement to the European Medicines Agency on 6 June 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 13 July 2011.

Supplementary information was provided by the applicant on 23 January 2012. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population, and with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 April 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of major depressive episodes

The waiver applies to:

- All subsets of the paediatric population from birth to less than seven years of age;
- for film-coated tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in children from birth to less than 24 months of age;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible in children from 2 years to less than 7 years of age.

1.2. Condition: Treatment of generalised anxiety disorder

The waiver applies to:

- All subsets of the paediatric population from birth to less than seven years of age;
- for film-coated tablets for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of major depressive episodes

2.1.1. Indication(s) targeted by the PIP

Treatment of major depressive episodes.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 7 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	**Study 1:** 10 weeks toxicity study of Agomelatine in juvenile rats.

Area	Number of studies	Description
Clinical	3	**Study 2:** Open-label, multicentre, three dose levels, trial to evaluate pharmacokinetics of Agomelatine in children from 7 to less than 18 years of age with major depressive disorder. **Study 3:** Double blind, randomised, multicentre, two dose levels, active and placebo controlled, trial to evaluate efficacy and safety of Agomelatine to treat children from 7 to less than 18 years of age with major depressive disorder. **Study 4:** Double blind, randomised, multicentre, one dose level, placebo controlled, trial to prevent depressive relapse of Agomelatine in children from 7 to less than 18 years of age with major depressive disorder.

2.2. Condition: Treatment of generalised anxiety disorder

2.2.1. Indication(s) targeted by the PIP

Treatment of generalised anxiety disorder.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 7 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Film-coated tablet.

2.2.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	**Study 1:** Same study as for condition “Treatment of major depressive episodes”

Area	Number of studies	Description
Clinical	2	**Study 5:** Double blind, randomised, multicentre, two dose levels, placebo controlled, trial to evaluate efficacy and safety of Agomelatine in children from 7 to less than 18 years of age with generalised anxiety disorder. **Study 6:** Double blind, randomised, multicentre, one dose level, placebo controlled, trial to evaluate prevention of anxious relapse of Agomelatine in children from 7 to less than 18 years of age with generalised anxiety disorder.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2022
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of major depressive episodes

Authorised indications: Treatment of major depressive episodes in adults

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
EU/1/08/499/001	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	7 tablets
EU/1/08/499/002	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	14 tablets
EU/1/08/499/003	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	28 tablets
EU/1/08/499/004	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	42 tablets
EU/1/08/499/005	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	56 tablets
EU/1/08/499/006	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	84 tablets
EU/1/08/499/007	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	98 tablets
EU/1/08/499/008	Valdoxan	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	100 tablets

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Package size
EU/1/08/498/001	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	7 tablets
EU/1/08/498/002	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	14 tablets
EU/1/08/498/003	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	28 tablets
EU/1/08/498/004	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	42 tablets
EU/1/08/498/005	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	56 tablets
EU/1/08/498/006	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	84 tablets
EU/1/08/498/007	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	98 tablets
EU/1/08/498/008	Thymanax	25 mg	Film-coated tablet	Oral use	blister (PVC/alu)	100 tablets